Orlando Oliveira
Chief Executive Officer
Replay available
Santhera Pharmaceuticals Holding AG (0QN1) Q2 2026 Earnings Call
Santhera Pharmaceuticals Holding AG (LSE: 0QN1) Q2 2026 earnings conference call, held 2026-09-30. Replay captured from the company's public earnings webcast.
Investor webinar replay
Meeting Overview The Santerra Pharmaceuticals Holdings AG half-year results investor presentation focused on the company's achievements and market developments for the first half of 2026. Key highlights included successful market access initiatives, strategic partnerships, and regulatory advancements. Key Discussion Points - Overview of the half-year results for 2026. - Achievements in market access across major EU markets, including Spain, Italy, Germany, and the UK. - Strategic licensing agreement with Nexera for APAC markets, including Japan and South Korea. - Regulatory approvals and reimbursement discussions in various European countries. - Growth in sales volumes and market share for Agamri in key territories. - Updates on executive and board changes within the company. - Expansion of distribution partnerships in Central Eastern Europe and Central Asia. - Future plans for market entry into Latin America. Decisions Made - No explicit decisions recorded. Action Items & Next Step...
Latest press releases
- SIX:SANN — Santhera Expands Biomedica Agreement to Extend AGAMREE® (Vamorolone) Distribution Across Central Asia and the Caucasus · Mon, Jul 13, 2026
- SIX:SANN — Santhera Announces Orphan Drug and Priority Review Designations for AGAMREE® (Vamorolone) in South Korea · Tue, Jun 2, 2026
Companies on this event
Featured Presenters
Dr Shabir Hasham
Chief Medical Officer
Catherine Isted
Chief Financial Officer
Replay transcript excerpt
Speaker 1: Good afternoon and welcome to the Santerra Pharmaceuticals Holdings AG half-year results investor presentation. The hours recorded in meeting investors will be in listen-only mode. Questions can be submitted at any time by the Q&A tab situated in the right-hand corner of your screen. Just simply type in your question and press send. The company may not be in a position to answer every question received during the meeting itself. However, the company can review all questions submitted and publish responses where it's appropriate to do so. Speaker 1: Before we begin, I'd like to submit the following poll. Speaker 1: I'd now like to hand you over to the Santerra Pharmaceuticals Holdings team. Good afternoon. Speaker 2: Good afternoon and welcome to the 1st 0.5 results for the 6 months ending the 30th of June, 2026. Speaker 2: Giving the presentation today will be our new CEO, Speaker 2: Orlando Oliveira, Speaker 2: myself, Catherine Isted Speaker 2: and our Chief Medical Officer, Dr. Shabir Hassan. Speaker 2: Can I please encourage you to type in questions into the Q&A box as we go along, and we will answer these at the end of the presentation? Speaker 2: As always, we have a disclaimer. Please feel free to read this at your leisure. Speaker 2: I now hand over to Orlando to go through the highlights of the 1st 0.5 of the year. Speaker 3: Thank you very much, Catherine. Good afternoon, everyone. Speaker 3: 2026 has been a strong year so far, and we have achieved a lot of success in terms of market access initiatives. Speaker 3: I would like to take you through a few of our major achievements during the 1st 6 months. Speaker 3: The 1st 1, Clearly, 4 out of the 5 major EU markets now are commercially launched. Pricing reimbursement has been secured in Spain and ...